Table of Contents 2
List of Tables 6
List of Figures 6
LG Life Science LTD. Spshot 7
LG Life Science LTD. Overview 7
Key Facts 7
LG Life Science LTD. - Research and Development Overview 8
Key Therapeutic Areas 8
LG Life Science LTD. - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Combition Treatment Modalities 14
Pipeline Products - Partnered Products 15
Partnered Products/Combition Treatment Modalities 16
Pipeline Products - Out-Licensed Products 17
Out-Licensed Products/Combition Treatment Modalities 18
LG Life Science LTD. - Pipeline Products Glance 19
LG Life Science LTD. - Late Stage Pipeline Products 19
Pre-Registration Products/Combition Treatment Modalities 19
Phase III Products/Combition Treatment Modalities 20
LG Life Science LTD. - Clinical Stage Pipeline Products 21
Phase II Products/Combition Treatment Modalities 21
Phase I Products/Combition Treatment Modalities 22
LG Life Science LTD. - Early Stage Pipeline Products 23
Preclinical Products/Combition Treatment Modalities 23
Discovery Products/Combition Treatment Modalities 24
LG Life Science LTD. - Unknown Stage Pipeline Products 25
Unknown Products/Combition Treatment Modalities 25
LG Life Science LTD. - Drug Profiles 26
(gemigliptin + glimepiride) - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
(gemigliptin + metformin hydrochloride) - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
(gemigliptin + rosuvastatin calcium) - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
(lercanidipine hydrochloride + valsartan) - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
adalimumab biosimilar - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
etanercept biosimilar - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Eupenta - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
exetide SR - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
infliximab biosimilar - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
interferon alfa-2a SR - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
LBDE - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
LBVC - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
LBVD - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
LBVE-013 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
LBVE-014 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
LC-231306 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
LC-280126 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
LC-280391 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
LC-34AD3 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
LC-350189 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
LC-541239 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
LC-65AOD3 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
LD-02GIFRO - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Monoclol Antibody to Inhibit VEGF for Cancer - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
NecX - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
nivocasan - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
rituximab biosimilar - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Small Molecule to Inhibit PAR-1 for Atherothrombosis - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecules for Obesity - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecules to Inhibit 20S Proteasome for Multiple Myeloma and Solid Tumor - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
somatropin - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
somatropin SR - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
LG Life Science LTD. - Pipeline Alysis 59
LG Life Science LTD. - Pipeline Products by Target 59
LG Life Science LTD. - Pipeline Products by Route of Administration 62
LG Life Science LTD. - Pipeline Products by Molecule Type 63
LG Life Science LTD. - Pipeline Products by Mechanism of Action 64
LG Life Science LTD. - Dormant Projects 67
LG Life Science LTD. - Locations And Subsidiaries 68
Head Office 68
Other Locations & Subsidiaries 68
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71